The study, published in Frontiers in Lupus, evaluated SK1217 in a pristane-induced lupus mouse model, a widely used experimental system in which a single intraperitoneal injection of the mineral oil tetramethylpentadecane triggers lupus-like symptoms including autoantibody production, immune dysregulation, and renal damage. The researchers, Swetha Kakkerla, Sridhar Kavela, and Sathvika Chintalapani, initially screened four novel antimicrobial and immunomodulatory peptides, SK1203, SK1217, SK1260, and SK1281, for their ability to modulate the lupus-like disease. SK1217, a cationic peptide with the sequence AFWWKAKKFAWAKKFAWWKAW, demonstrated the most promising effects and was selected for detailed dose-response experiments at 1 and 2 mg/kg.

The experimental design was rigorous. Female BALB/c mice, eight weeks old, were randomly divided into six groups of six animals each. One group served as an untreated normal control, while the remaining five received 0.5 mL of pristane intraperitoneally. After an eight-week induction period, peptide treatments began at 2 mg/kg three times per week and continued until the mice reached 30 weeks of age. Serum samples collected at weeks 8, 16, and 30 allowed the team to track disease progression longitudinally, and kidney tissues were examined at the endpoint by light microscopy and Western blotting.

The results on autoantibodies were striking. Vehicle-treated lupus mice showed progressive, time-dependent increases in anti-nuclear antibodies, anti-double-stranded DNA, and anti-nRNP/Sm antibodies, confirming successful disease induction. By week 30, SK1217-treated mice exhibited marked reductions in all of these autoantibodies, as well as in anti-chromatin and anti-single-stranded DNA IgG levels measured by indirect ELISA. Because these autoantibodies form immune complexes that deposit in tissues, activate complement, and recruit inflammatory cells, their suppression represents a direct attack on one of the central mechanisms driving organ damage in lupus.

The peptide also proved to be a potent anti-inflammatory agent. Serum concentrations of the proinflammatory cytokines TNF-α, IL-1β, IL-6, and IL-17, all implicated in lupus pathogenesis and correlated with disease activity, were significantly elevated in vehicle-treated lupus mice but fell substantially after SK1217 treatment, approaching levels seen in non-lupus controls. Mechanistically, Western blot analysis of renal tissue revealed that SK1217 downregulated NF-κB p65 expression and reduced the phosphorylation of JNK and p38 MAPK, two stress-activated kinases central to inflammatory signaling and lupus nephritis progression. This concurrent inhibition of two major intracellular cascades suggests the peptide disrupts the signaling infrastructure that sustains renal inflammation.

Perhaps the most mechanistically revealing findings concerned the humoral immune system. Pristane-induced lupus mice showed elevated serum levels of B-cell activating factor, or BAFF, a cytokine that promotes B cell survival, activation, and plasma cell differentiation. SK1217 treatment at both doses significantly reduced BAFF concentrations. Flow cytometric analysis of splenocytes further showed that the peptide decreased the proportion of CD40-positive activated B cells and CD138-positive plasma cells, accompanied by reduced total serum IgG. This coordinated suppression of BAFF-driven B cell amplification provides a coherent explanation for the observed drop in circulating autoantibodies and positions SK1217 alongside belimumab, the approved anti-BAFF monoclonal antibody, as a therapeutic strategy targeting the same pathway.

Renal protection was equally impressive. Vehicle-treated lupus mice exhibited elevated serum creatinine and blood urea nitrogen, hallmarks of impaired kidney function, along with reduced complement C3 levels consistent with complement consumption by immune complex deposition. SK1217 treatment normalized creatinine and BUN, restored C3 toward control levels, and significantly reduced urinary protein excretion measured over 24-hour metabolic cage collections. Histopathological examination of hematoxylin and eosin-stained kidney sections confirmed reduced glomerular damage in treated animals, providing morphological corroboration of the functional biomarkers.

Notably, the peptide did not act as a blunt immunosuppressant. Flow cytometry of peritoneal lavage cells showed that total peritoneal exudate cell numbers were unchanged between treated and untreated lupus mice, indicating no global depletion of immune cells. Instead, SK1217 selectively reduced the frequency of Ly6C-high inflammatory monocytes, a subset known to drive autoantibody production through type I interferon secretion in a Toll-like receptor 7-dependent manner, while decreasing peritoneal IFN-γ levels. Interestingly, granulocyte numbers increased in the treated group, suggesting a reshaping rather than a wholesale suppression of innate immunity.

The therapeutic landscape for lupus remains constrained. Conventional management relies on glucocorticoids, methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide, all of which carry significant long-term toxicity and infection risk, while the heterogeneity and unpredictable course of the disease make uniform treatment responses elusive. Therapeutic peptides offer theoretical advantages including high specificity, low immunogenicity, and modifiable structures, and prior work has shown that cationic host-defence peptides can attenuate lupus-associated immune activation in preclinical models. Challenges such as proteolytic degradation, short half-life, and synthesis cost, however, have historically limited their clinical translation.

The authors conclude that SK1217 exerts multi-target immunomodulatory and renoprotective effects through coordinated suppression of BAFF-driven B cell activation, inflammatory cytokine production, complement activation, and MAPK/NF-κB signaling. They emphasize that further research is needed to fully elucidate the peptide’s mechanisms, evaluate its long-term safety, and explore potential synergies with existing lupus therapies. If those translational steps succeed, SK1217 could represent a genuinely novel class of lupus treatment, one that modulates rather than obliterates the immune system, and one whose journey from a Hyderabad laboratory to the clinic will be watched closely by researchers and patients alike.

Subject of Research: SK1217 peptide efficacy in pristane-induced lupus mice

Article Title: Evaluating the efficacy of SK1217 in attenuating pristane-induced lupus in mice

Article References: Kakkerla, S., Kavela, S., & Chintalapani, S. (2026). Evaluating the efficacy of SK1217 in attenuating pristane-induced lupus in mice. Frontiers in Lupus, 4, Article 1466123. https://doi.org/10.3389/flupu.2026.1466123

Image Credits: AI Generated

DOI: 10.3389/flupu.2026.1466123

Keywords: SK1217, systemic lupus erythematosus, lupus nephritis, pristane model, BAFF, autoantibodies, MAPK/NF-κB signaling, immunomodulatory peptide, renal protection, preclinical study, Evaluating, efficacy

Locomotor sensitization is a cornerstone paradigm in addiction neuroscience. When an animal receives repeated doses of a psychostimulant such as nicotine, its spontaneous movement in response to the drug does not stay constant; instead, the locomotor response grows progressively stronger with each exposure. This escalation is thought to mirror long-lasting neuroadaptations in the mesolimbic dopamine system, the same circuitry that mediates craving and drug seeking in humans. Because sensitization can persist for weeks after the last dose, researchers use it as a measurable proxy for the latent brain changes that make relapse so likely. A drug that suppresses the expression of sensitization is therefore considered a candidate for reducing the neural drive behind addiction.

Agomelatine occupies a distinctive pharmacological niche. Unlike classical antidepressants that primarily target monoamine reuptake, agomelatine is a melatonergic agent: it activates MT1 and MT2 melatonin receptors while blocking serotonin 5-HT2B and 5-HT2C receptors. This dual profile underlies its antidepressant and sleep-regulating effects and has made it attractive for disorders in which circadian disruption and mood pathology overlap. Importantly for the present study, the same laboratory had previously shown that agomelatine decreases the reinforcing and neurochemical effects of cocaine in Wistar rats, raising the question of whether its anti-addiction properties extend to nicotine, a drug with a very different primary mechanism acting through nicotinic acetylcholine receptors.

To find out, the researchers turned to the nicotine locomotor sensitization paradigm, one of the most widely used behavioral screens in preclinical addiction research. In this model, rats are given repeated nicotine administrations across several days while their horizontal movement is recorded in activity monitors. The design allowed the team to separate two distinct questions: whether agomelatine changes the acute locomotor activation produced by nicotine itself, and whether it interferes with the expression of sensitization, the amplified response that emerges after repeated dosing. The distinction matters clinically, because the expression phase is thought to reflect the established neuroadaptations that persist into withdrawal and craving.

The results were clear on both fronts. When agomelatine was administered at a dose of 10 milligrams per kilogram intraperitoneally during the expression phase and during nicotine withdrawal, it attenuated the expression of locomotor sensitization induced by multiple doses of nicotine. In practical terms, rats that had been sensitized by repeated nicotine no longer showed the exaggerated locomotor response once they received agomelatine. The drug also shortened the duration of the locomotor effects and reduced overall locomotor activity after binge nicotine administration, meaning that both the intensity and the time course of nicotine’s behavioral impact were blunted.

These findings fit into a broader mechanistic picture. Nicotine’s sensitizing effects depend heavily on dopamine release in the nucleus accumbens and on glutamatergic and serotonergic modulation of ventral tegmental area neurons. By antagonizing 5-HT2C receptors, agomelatine indirectly enhances dopaminergic and noradrenergic tone in frontal regions, while its melatonergic activity may normalize circadian signaling that is disrupted in addiction. The authors note that the drug’s prior success against cocaine-induced sensitization and reinforcement, combined with the present nicotine data, suggests a convergent action on shared final pathways of psychostimulant sensitization rather than on nicotine’s specific receptor target.

The clinical context gives the result its urgency. Smoking remains the leading preventable cause of death worldwide, and current cessation pharmacotherapies, including nicotine replacement, varenicline, and bupropion, leave a substantial fraction of smokers unable to quit permanently. Because agomelatine is already approved for depression in many countries, has a known safety profile, and addresses the mood and sleep disturbances that often accompany nicotine withdrawal, a repurposing strategy is attractive. If sensitization in rodents reflects the human phenomena of craving and relapse, a drug that suppresses sensitization expression could theoretically reduce the pull of cigarette cues during abstinence.

The authors are careful, however, about the limits of the present evidence. Their conclusions state that the results support the need for further preclinical studies before proposing agomelatine for clinical trials in smoking cessation. The study was conducted exclusively in male rats, so sex differences, which are well documented in nicotine reinforcement, remain unexplored. The dose was delivered intraperitoneally, a route that does not translate directly to human oral dosing, and the behavioral endpoint was locomotion rather than drug self-administration or relapse-like behavior, which are closer analogues of human addiction.

Methodological rigor in the study was supported by ethical approval from the Institutional Animal Care and Bioethics Committee under protocols CICUAL/0003/2022 and CEI/C/IC22177015/2022, conducted in compliance with the NIH Guide for the Care and Use of Laboratory Animals. The work was funded by grants INP-2000-2040 and CI-IC092020.2, and the authors declared no competing interests. The article was received in April 2026, accepted in October 2026, and published on 13 October 2026 as an open-access contribution to BMC Pharmacology and Toxicology, making the full dataset available to the research community without paywall.

For the field of addiction pharmacotherapy, the study is a proof of concept rather than a prescription. It demonstrates that a melatonergic antidepressant with serotonergic antagonist properties can reach into the neural machinery of nicotine sensitization, a finding that invites follow-up work with self-administration models, female subjects, and withdrawal-related measures such as anhedonia and anxiety. If those experiments confirm and extend the present results, agomelatine could join a small group of repurposed psychiatric drugs being tested not for their original indication but for their ability to weaken the grip that nicotine exerts on the addicted brain.

Subject of Research: Effects of the melatonergic antidepressant agomelatine on nicotine-induced locomotor sensitization in male rats

Article Title: Agomelatine attenuates the expression of nicotine-induced locomotor sensitization in male rats

Article References: Barbosa-Méndez, S., & Salazar-Juárez, A. (2026). Agomelatine attenuates the expression of nicotine-induced locomotor sensitization in male rats. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01260-7

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01260-7

Keywords: agomelatine, nicotine, locomotor sensitization, addiction, melatonin receptors, serotonin receptors, smoking cessation, psychostimulant, preclinical study, rats, neuropharmacology, antidepressant

The obstacle that has defeated photodynamic therapy, or PDT, in pigmented melanoma is fundamentally optical and chemical. PDT relies on photosensitizing drugs that, when illuminated with light of a specific wavelength, generate reactive oxygen species, including excited-state singlet oxygen, that kill tumor cells directly or shut down the blood vessels feeding the tumor. Melanin undermines this at every step: it absorbs and scatters light so effectively that very little reaches deeper tissue, and it chemically neutralizes reactive oxygen species before they can inflict lethal damage. Many melanoma cells also actively pump photosensitizers back out of the cell. In measurements on excised S91 murine melanoma reported in the new study, transmission of 690-nanometer treatment light fell by four orders of magnitude through just 2 millimeters of tissue, and light became undetectable beyond 3 millimeters.

The research team, led by L. Pires and B. C. Wilson of Texas A&M University and the Princess Margaret Cancer Center in Toronto, did not try to blast through this barrier with ever-stronger light. Instead, they paired two photosensitizers already in clinical use: Photodithazine, a chlorin e6 derivative that concentrates in tumor cells, and Visudyne, a liposomal benzoporphyrin formulation that targets the tumor microvasculature. Each drug was illuminated at its own red absorption peak, delivered through an optical fiber, and a topically applied optical clearing agent made of PEG-400 and propanediol was rubbed into tape-stripped skin to reduce light scattering and improve penetration. The protocol was first shown to eradicate thin, pigmented tumors, but in immunodeficient mice the animals still succumbed to metastatic spread.

The decisive change in the new work was testing the identical protocol in mice with intact immune systems, and against tumors deliberately grown to 3 to 4 millimeters thick, several times deeper than any effective light dose could reach. In immunocompetent DBA mice, the treated tumor site became intensely inflamed within hours, ulcerated within days, and healed completely by about three weeks, leaving no trace of tumor. Nineteen of 20 treated mice, 95 percent, survived to the 90-day endpoint without disease. In nude mice lacking T cells, the same treatment produced only superficial damage, and every animal died of tumor overgrowth with a median survival of just 21 days, indistinguishable from untreated controls. The dramatic split between the two groups is, the authors argue, only explicable if the immune system finished what the light started.

How could light that penetrates only the top millimeter of a tumor destroy the entire mass? The answer, according to the study’s mechanistic analysis, is that the photodynamic damage to the superficial layer acts as a biological alarm. Dying cancer cells release damage-associated molecular patterns such as calreticulin, ATP and HMGB1, molecules that alert dendritic cells and other antigen-presenting cells. These cells ingest tumor debris, carry tumor antigens to the draining lymph nodes, and prime cytotoxic CD8-positive T cells that can recognize and kill melanoma cells anywhere in the body, including regions the light never touched. The researchers have named this cascade photodynamic immune stimulation, or PDIS.

The immune signatures measured after treatment were striking in their breadth and speed. Within three to six hours, CD3-positive T cells and CD19-positive B cells flooded into the tumor, while populations of Ly-6G-positive, Ly-6C-positive myeloid cells associated with immunosuppression fell. By 12 hours, immunohistochemistry showed T cells distributed throughout the tumor parenchyma, not merely clustered at the margins. In blood, eosinophils rose sharply while circulating lymphocytes dropped, consistent with migration toward the tumor, and activated CD69-positive T cells increased in both blood and lymph nodes. Plasma levels of inflammatory messengers including IL-2, IL-6, IL-18, ENA-78 and GRO-alpha surged, returning toward baseline by two weeks.

Gene expression profiling of treated tumors revealed a wholesale transcriptional shift, most pronounced at 24 hours. Gene Ontology analysis showed enrichment of pathways governing lymphocyte differentiation, cytokine signaling, leukocyte proliferation and myeloid cell differentiation, while KEGG pathway analysis highlighted IL-17 signaling, chemokine signaling, natural killer cell-mediated cytotoxicity, T-cell and B-cell receptor signaling, Toll-like receptor signaling and pathways of apoptosis and cellular senescence. Most tellingly, T cells in the draining lymph nodes shifted over time from naive and central-memory phenotypes toward effector-memory cells, the population capable of rapid cytotoxic attack on re-encountering tumor antigens, the cellular signature of durable immune memory.

A series of functional experiments made the causal case. When CD8-positive T cells were depleted with antibodies before treatment, five of six mice died of tumor overgrowth within 34 days, collapsing the 95 percent disease-free survival down toward control levels and proving that cytotoxic T cells are the dominant effectors. In adoptive transfer experiments, splenocytes from treated mice mixed with melanoma cells and injected into healthy recipients slowed tumor growth dramatically, without any attack on healthy tissue, indicating tumor-specific memory. In mice bearing tumors on both flanks, treating only one tumor completely eradicated it and significantly delayed growth of the untreated opposite tumor, an abscopal effect that extended median survival from 6 to 15 days. Finally, when mice cured 30 days earlier were injected intravenously with a million melanoma cells, all remained tumor-free, while every control mouse developed bulky lung and peritoneal metastases.

The authors are careful about the limits of the work. All experiments used male mice and a single murine melanoma cell line, so the findings must be validated across genetically diverse models before clinical translation. They also note that the light gradient through pigmented tissue may generate different cell death pathways at different depths, potentially shaping the strength of the immune response, a relationship they are now investigating to optimize dosing. Even so, male mice are known to mount weaker immune responses than females, making the observed effect particularly notable, and the fact that melanin’s barrier could be sidestepped rather than defeated challenges two decades of assumptions in the field.

The clinical possibilities outlined by the team are tantalizing. PDIS could be delivered shortly before surgical resection, exploiting the perioperative window to counter the immune suppression that surgery itself induces and to attack unsuspected micrometastases. Its ability to convert immunologically cold tumors into hot ones suggests rational combination with immune checkpoint inhibitors, preclinical studies of which are planned. The measured immune biomarkers could guide patient selection and real-time monitoring, extending dosimetry beyond drug uptake and light dose to include the tumor’s immune landscape. The same principle may extend to uveal melanoma, where the group’s multiphoton PDT work has already shown lymphocyte activation with partial tumor targeting, and to immunotherapy-resistant cancers such as pancreatic and lung tumors. For a disease whose five-year survival collapses to roughly 30 percent once it metastasizes, a low-toxicity treatment that both destroys the primary tumor and vaccinates the body against recurrence would represent a genuinely new chapter in melanoma care.

Subject of Research: Photodynamic immune stimulation as an immunotherapy strategy for pigmented melanoma

Article Title: Photodynamic immune stimulation eradicates primary pigmented melanoma and induces long-lasting anti-tumor immunity

Article References: Pires, L., Calcada, C., Cerqueira-Rodrigues, B., Fan, Y., George, J. T., McGaha, T., & Wilson, B. C. (2026). Photodynamic immune stimulation eradicates primary pigmented melanoma and induces long-lasting anti-tumor immunity. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03585-w

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03585-w

Keywords: melanoma, photodynamic therapy, immunotherapy, photosensitizers, CD8 T cells, abscopal effect, immune memory, tumor microenvironment, optical clearing, immunogenic cell death, preclinical study, British Journal of Cancer

The STING pathway, short for stimulator of interferon genes, is the cellular alarm system that senses misplaced DNA. Under normal conditions, the enzyme cGAS detects cytosolic DNA, often released by viruses or damaged cells, and manufactures cyclic dinucleotides that bind to STING, a protein anchored in the endoplasmic reticulum. This binding triggers a conformational change that recruits the kinase TBK1, which in turn phosphorylates the transcription factors IRF3 and NF-kappaB, unleashing a burst of type I interferons and proinflammatory cytokines. In cancer biology, this pathway is doubly important: radiotherapy itself depends on cGAS/STING signalling in immune cells for much of its anti-tumour effect, and dendritic cells, which express high levels of STING, are thought to be the critical translators of tumour cell death into productive T cell immunity.

The London-led team set out to establish whether BI 1703880 could reliably switch this machinery on. Using paired THP-1 reporter cell lines, one carrying functional STING and one knocked out by CRISPR/Cas9, they demonstrated that the compound drives robust phosphorylation of STING, TBK1 and IRF3 only where the target protein is present, confirming strict on-target specificity. The same dose-dependent pathway activation appeared in primary human peripheral blood mononuclear cells from three independent donors. Importantly, because human STING exists in five major genetic variants, the researchers engineered reporter cells expressing each variant and found that the agonist engaged all five, a property that could matter enormously for translating the drug across genetically diverse patient populations.

RNA sequencing deepened the picture. Treated THP-1 cells and human donor-derived dendritic cells showed a clear induction of interferon-related genes, cytokine transcripts and, notably, the HLA-A, HLA-B and HLA-C genes that present antigens to cytotoxic CD8-positive T cells. Bio-Plex assays confirmed corresponding secretion of IFN-alpha, IFN-beta, IFN-lambda, CXCL10, CCL2, CCL5 and TNF-alpha. In short, the compound did exactly what a dendritic-cell-targeted adjuvant should do: it converted these sentinels into a state primed for cross-presentation and T cell priming.

The in vivo work, however, revealed a fundamental dose dilemma. In mice bearing anaplastic thyroid carcinoma, head and neck squamous cell carcinoma and colorectal tumours, a single high intravenous dose of 20 micromoles per kilogram produced plasma cytokine surges ranging from 1,000 to 60,000 picograms per millilitre, accompanied by dramatic haemorrhagic tumour necrosis and rapid shrinkage within 72 hours. The speed and vascular character of that response suggested effects beyond the desired immunology. Low doses of 7 micromoles per kilogram generated far more modest, transient cytokine peaks that returned to baseline in the blood within 24 hours. The team also noted that a mouse model expressing a constitutively active STING mutation suffers lethal hypercytokinemia, a reminder that chronic, excessive interferon signalling is dangerous. Repeated low-dose treatment, by contrast, caused no significant weight loss and was selected as the foundation for combination studies.

Radiotherapy emerged as the natural partner. The investigators deliberately chose a sub-therapeutic regimen of two 8 Gy fractions on consecutive days, sufficient to slow tumours but not to control them, and increased tumour MHC class I and PD-L1 expression. When repeated low-dose STINGa was layered onto this irradiation in mice with TBPt-4C4 or mEER tumours, the combination significantly improved both tumour control and survival compared with either therapy alone, and mice that achieved cure rejected a subsequent tumour rechallenge, evidence of genuine adaptive immune memory. The synergy held in five additional subcutaneous models, including MC38, TC-1, AT84 and two further thyroid cancer lines, and in orthotopic mEER tumours growing in the lip.

Mechanistically, the combination proved strictly immune-dependent. In immunodeficient NSG mice lacking lymphocytes, the benefit of RT/STINGa collapsed, and antibody-mediated depletion of CD8-positive T cells in wild-type mice similarly eroded tumour control. Spectral flow cytometry using the Nr4a3-timer ‘Tocky’ transgenic reporter system, which tracks the temporal dynamics of T cell receptor signalling, revealed that combination therapy expanded a distinct cluster of intratumoural CD8-positive T cells showing persistent cognate antigen signalling. These cells were highly proliferative, expressing Ki67, activated as shown by CD69, and cytotoxic, indicated by granzyme B, but simultaneously displayed elevated PD-1, CD44, TIM3 and ICOS, hallmarks of an activated-but-exhausted phenotype. The tumour microenvironment itself became measurably more inflamed, with interferon signalling transcripts upregulated and the CD8-to-Treg ratio rising favourably.

That exhaustion signature pointed directly toward checkpoint blockade. Bulk RNA sequencing of tumours treated with the double combination confirmed upregulation of the Pdcd1 and Ctla4 axes, and the team therefore added anti-PD-1 and anti-CTLA-4 antibodies to create a quadruple regimen. The results were striking. In the TBPt-4C4 model, quadruple therapy cured five of six mice, compared with one of six receiving RT/STINGa with isotype controls, while in mEER tumours six of six mice achieved cure. Histology two weeks after treatment initiation showed extensive central necrosis, fibrosis and chronic inflammation with scant residual viable tumour, and increased CD8 infiltration together with elevated granzyme and perforin transcripts suggested restored cytotoxic function rather than merely more T cells. In the TKP-4831 model, cures were not achieved but survival was significantly prolonged.

A bilateral flank experiment added an intriguing systemic dimension. When only the right-sided tumour was irradiated while STINGa circulated systemically, the unirradiated left tumours did not shrink more under combination therapy than with STINGa alone, meaning no classic abscopal effect on growth was observed. Yet CD8-positive T cell infiltration into the unirradiated tumours increased following the combination, indicating that irradiation of one site can seed immune activity against distant disease, even if not yet to a therapeutically decisive degree. The authors also emphasised that the STINGa-induced cytokine response in their models appears to originate predominantly from host immune and stromal cells rather than tumour cells, since several of the tested cancer lines lacked detectable STING signalling and did not secrete interferon-beta upon treatment in vitro.

The study’s authors conclude that STING is firmly validated as a therapeutic target in cancer and that radiotherapy deserves recognition as a rational combination partner for systemically delivered agonists. BI 1703880 is already under evaluation in a phase I clinical trial, and the preclinical framework presented here, sub-therapeutic radiation followed by repeated low-dose systemic agonism and rationally selected checkpoint blockade, offers a roadmap for how such trials might be designed. With first-generation intratumoural agents such as MK-1454 and ADU-S100 having fallen short, the prospect of an intravenous drug that activates innate immunity across multiple tumour sites while synergising with standard radiotherapy represents a genuinely encouraging advance, though the ultimate test will lie in whether this carefully orchestrated immunology survives translation into patients.

Subject of Research: Preclinical evaluation of a systemically delivered STING agonist combined with radiotherapy and immune checkpoint blockade for cancer immunotherapy

Article Title: Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy

Article References: Pedersen, M., Hubbard, L. C., Foo, S., Patrikeev, A., Rullan, A., Baldock, H., Mandl, C., Chetta, P., Hassan, J., Dean, I., Guppy, N., Slos, P., Hak, C. C. W., Appleton, E., Patin, E. C., Hunt, R., Weir, J., Ono, M., Oost, T., … Harrington, K. J. (2026). Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03634-4

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03634-4

Keywords: STING agonist, BI 1703880, cancer immunotherapy, radiotherapy, cGAS-STING pathway, dendritic cells, CD8 T cells, immune checkpoint inhibitors, PD-1, CTLA-4, tumour microenvironment, preclinical study

The research, led by Agnes (Yu) Luo, PhD, professor in the UC College of Medicine and the study’s corresponding author, was published in the journal Fluids and Barriers of the CNS, a publication devoted to the specialized biology of cerebrospinal fluid and the barriers that protect the central nervous system. The work was supported by grant funding from the National Institutes of Health, underscoring its translational ambition: to move a laboratory discovery toward real-world medical practice for a condition that remains life-threatening despite more than half a century of modern neurosurgery.

To understand why the approach is significant, it helps to understand what cerebrospinal fluid does and what goes wrong in hydrocephalus. CSF circulates throughout the brain, supporting brain function, regulating brain development, and carrying nutrients, hormones, and signaling molecules. Hydrocephalus occurs when excess CSF builds up inside the brain, raising intracranial pressure that can compress delicate neural tissue and cause neurological impairment. The current standard of care requires invasive brain surgery to implant a shunt that drains the excess fluid, but shunts are notoriously prone to failure, blocking, breaking, or becoming infected, often necessitating revision surgeries. Neurosurgeons sometimes offer an alternative endoscopic approach that partially cauterizes the choroid plexus, the tissue that produces cerebrospinal fluid, but this can only improve symptoms without substantially reducing fluid volumes, and it is constrained by technical and safety limits. New, less invasive, and more comprehensive treatments are urgently needed.

The experimental therapy developed in Luo’s lab is built on an adeno-associated virus, or AAV, a modified virus that has become one of the most widely used vehicles in gene therapy because it can efficiently deliver therapeutic genetic material into a patient’s cells without causing disease. In this case, the AAV construct is designed to target and reduce the specific cell types that produce cerebrospinal fluid, limiting its production and its spread into brain tissue. Rather than mechanically draining fluid after it has accumulated, the therapy aims to turn down the tap itself.

“It efficiently targets the correct cells and reduces CSF production,” said Aleksandr Taranov, PhD, the study’s lead author, who was a neuroscience graduate student in Luo’s lab at the time of the research and is now a postdoctoral fellow at the University of Pennsylvania. The precision of that targeting matters enormously: the choroid plexus sits at the interface between blood and cerebrospinal fluid, and any therapy that disrupts it must hit the fluid-producing cells while sparing surrounding brain structures.

Equally notable is the potential route of delivery. Because many hydrocephalus patients already carry an implanted shunt, the therapy could conceivably be administered through that existing hardware, an injection through a device that is already in place. “This would allow us to have a minimally invasive and feasible treatment for hydrocephalus,” Taranov said. For a condition whose current treatments involve opening the skull or threading endoscopes deep into the ventricles, the prospect of a shunt-delivered gene therapy represents a strikingly less invasive alternative.

To explore the clinical implications, the Cincinnati team partnered with neurosurgery researchers at UC Davis, where Cameron Sadegh, MD, PhD, and Olga Chechneva, PhD, co-led the animal studies. The Davis team induced hydrocephalus in adult animal models and then treated them with the experimental gene therapy developed by Luo’s group. The treatment proved effective at preventing edema, the accumulation of excess fluid, from entering brain tissue outside the ventricles, the fluid-filled chambers where CSF normally resides. Preventing that parenchymal edema is critical, because fluid invading brain tissue is a major driver of the neurological damage hydrocephalus causes. The Cincinnati team then validated the findings with a blinded analysis of MRI data provided by the UC Davis team, adding an extra layer of rigor to the cross-institutional result.

“Hydrocephalus is a life-threatening condition, and our treatment options are surprisingly limited and outdated,” said Sadegh, a pediatric neurosurgeon-scientist and assistant professor in the UC Davis School of Medicine’s Department of Neurological Surgery. “Shunt treatment frequently fails, and alternative endoscopic treatments are not possible for many patients. We are eager to contribute to the preclinical development and safety testing of new, cell-targeted approaches to treat this devastating condition.” Chechneva, a project scientist in Sadegh’s lab, emphasized that the findings reach beyond therapy development. “Showing that choroid plexus ablation reduces brain swelling does more than point to a new therapy,” she said. “It sheds light on the mechanisms behind hydrocephalus and the brain injury it causes, knowledge that is critical for developing better treatments.”

The study builds directly on a 2024 paper from the Luo Lab published in the Proceedings of the National Academy of Sciences, in which the team became the first to directly ablate adult choroid plexus tissue, reducing cerebrospinal fluid in adult animal models. That result was considered a major breakthrough in the field, because it demonstrated for the first time that the fluid-producing tissue in adults could be selectively reduced. The new work extends that foundation by showing that a gene therapy approach can achieve a similar effect and, crucially, that doing so attenuates the brain swelling associated with hydrocephalus.

Important questions remain, and the researchers are candid about them. Cerebrospinal fluid plays a role in postnatal neurogenesis, the generation of new neurons after birth in the hippocampus, a brain region central to memory, and this process remains poorly understood. Because reducing CSF production is central to the therapy’s effectiveness, understanding any downstream effects on neurogenesis is a critical next step. Initial animal testing shows that a loss of CSF production moderately reduces the brain’s ability to produce new neurons. Yet Luo and Taranov note that the current state of hydrocephalus treatment leaves patients with a persistent, lifelong risk of repeated brain surgeries that can cumulatively diminish cognitive performance, so a careful risk/benefit analysis is needed to weigh reduced neurogenesis against the burden of repeated operations. Either way, Luo said, the results are clear: animal models that received the AAV gene therapy had much less fluid in their brain tissue. The next phase will test the therapy in larger animal models and human tissues, ideally followed by human clinical trials. “This is continuous work,” Luo said. Luo and Taranov are both inventors on a pending patent related to the work, and contributors from both labs, including Sage Hamm, Eric Kniffen, Joshua Peter, Felissa Wallace, Olivia Lullmann, and Lucas McClain at Cincinnati and Florian Mayrhofer at UC Davis, helped bring the proof of concept to fruition.

Subject of Research: AAV gene therapy targeting choroid plexus to reduce cerebrospinal fluid production in hydrocephalus

Article Title: University of Cincinnati study shows proof-of-concept for hydrocephalus gene therapy

Article References: University of Cincinnati study shows proof-of-concept for hydrocephalus gene therapy. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hydrocephalus, gene therapy, adeno-associated virus, cerebrospinal fluid, choroid plexus, University of Cincinnati, UC Davis, shunt surgery, brain edema, neurogenesis, preclinical study, Fluids and Barriers of the CNS

The logic of TIL therapy rests on a simple observation: many tumors are not immunological deserts. Immune cells, particularly T lymphocytes, physically penetrate tumor tissue, where they can recognize mutated or aberrantly expressed proteins and kill the malignant cells they encounter. The therapeutic strategy involves harvesting a piece of the patient’s tumor, isolating the lymphocytes trapped inside, expanding them to billions of cells in the laboratory, and then reinfusing this amplified army back into the patient, usually after lymphodepleting chemotherapy creates immunological space. The approach has produced durable complete responses in a substantial fraction of advanced melanoma patients and is being tested in cervical cancer, lung cancer, and sarcomas. Whether it could work in NF1- and SWN-related tumors, however, had never been systematically examined, leaving a significant gap for a patient population with few options.

The first question the researchers addressed was whether these tumors actually harbor the T cell infiltrates that TIL therapy requires. They examined 109 clinical specimens spanning the disease spectrum, including benign neurofibromas from NF1 patients, schwannomas from SWN patients, and MPNSTs. Using immunohistochemistry to detect the pan-T cell marker CD3, they found moderate to high T cell infiltration in the overwhelming majority of samples: 84.0 percent of neurofibromas, 98.3 percent of schwannomas, and 75.0 percent of MPNSTs. This was a critical finding, because it established the biological prerequisite for the therapy. If the tumors had been largely devoid of T cells, harvesting and expanding meaningful numbers of tumor-reactive lymphocytes would have been futile. Instead, the data suggested that immune cells are already trafficking into these lesions in most patients, presumably drawn by tumor-associated antigens.

With the rationale established, the team turned to the practical challenge of growing these cells outside the body. Traditional TIL manufacturing relies on high-dose interleukin-2 (IL-2), a potent growth factor that drives T cell proliferation but can also skew the resulting cell population, exhaust the cells, and lengthen production times. The researchers developed an alternative protocol, designated OM-400, that combines stimulation through CD3 and CD28, the two key signaling receptors on T cells, using antibody-coated beads, with a much lower dose of IL-2 at 400 international units per milliliter. The CD3/CD28 co-stimulation mimics the two signals a T cell normally receives when it recognizes its target, providing activation in a more physiological manner than flooding the culture with cytokine alone.

The results of the head-to-head comparison were striking. OM-400 achieved successful expansion in 100 percent of the TIL cultures derived from NF1/SWN-related nerve sheath tumors, whereas the traditional high-dose IL-2 method did not consistently reach that benchmark. The new protocol also shortened the time required to grow the cells to therapeutic numbers, an important consideration for patients with aggressive MPNSTs who cannot afford to wait weeks for a product. Flow cytometric analysis showed that OM-400 cultures were enriched for CD8-positive effector T cells, the cytotoxic subset responsible for directly killing tumor cells. In an analysis of one representative specimen, the protocol also showed preliminary evidence of better preservation of the original T cell receptor (TCR) repertoire, meaning the diverse array of antigen-recognition specificities present in the patient’s tumor was maintained through the expansion process rather than being narrowed by overgrowth of a few clones.

Functionally, the OM-400-expanded cells proved more potent. When co-cultured with autologous tumor cells, meaning tumor cells taken from the same patient whose lymphocytes were being expanded, the cells produced under the new protocol showed enhanced tumor-reactive cytotoxicity, killing more cancer cells than their conventionally grown counterparts. They also secreted higher levels of interferon-gamma (IFN-γ), a signature inflammatory cytokine released when T cells genuinely recognize their targets. Together, these assays indicated that the OM-400 product was not merely larger in number but qualitatively better: more cytotoxic, more tumor-reactive, and more faithful to the immune landscape of the original tumor.

An important exploratory analysis examined whether the type of tumor influenced TIL performance. The team compared results across 15 independent patient samples covering NF1-related neurofibromas, SWN-related schwannomas, and NF1-related MPNSTs. No statistically significant differences emerged among the subtypes, suggesting that a single manufacturing platform might serve the entire disease spectrum. The authors are careful to note, however, that the study was not powered to establish equivalence, and larger cohorts will be needed to definitively assess whether tumor subtype affects TIL yield, phenotype, or reactivity. This caveat reflects the rarity of these conditions; collecting large numbers of fresh surgical specimens from NF1 and SWN patients is inherently difficult, making the 15-sample dataset a meaningful start rather than a final answer.

The decisive test came in animal models. The researchers used patient-derived xenografts (PDX), in which fragments of an MPNST patient’s tumor are implanted into immunodeficient mice, preserving the molecular characteristics of the original cancer. When OM-400-expanded TILs were delivered to these tumor-bearing mice, the cells successfully infiltrated the tumor tissue, a nontrivial requirement since many cell therapies fail because they cannot physically reach and penetrate the tumor mass. More importantly, the treated animals showed significant suppression of tumor growth compared with controls. This in vivo efficacy demonstrated that the laboratory-manufactured cells retained their killing capacity in a living biological system, not just in a culture dish, and provided the strongest evidence yet that the approach could translate to patients.

The significance of the work extends beyond a single protocol. NF1 affects approximately one in 2,500 to 3,000 births worldwide, and while most neurofibromas are benign, they can cause disfigurement, pain, and neurological deficits, and a subset progresses to life-threatening MPNSTs, for which five-year survival remains poor even with aggressive surgery, radiation, and chemotherapy. Recent years have seen encouraging but limited progress with targeted agents such as MEK inhibitors for inoperable plexiform neurofibromas, yet MPNST has remained essentially untouched by systemic therapy. A cellular immunotherapy platform that works across the NF1/SWN tumor spectrum would represent an entirely new therapeutic modality for these patients, and one that could in principle be personalized to each individual’s tumor.

Considerable work remains before the first patient receives an infusion. The study is preclinical, and the transition from PDX mice to human trials will require regulatory-grade manufacturing, safety testing, and careful attention to questions the current data cannot answer, such as the durability of responses, the optimal lymphodepletion regimen, and whether the TCR repertoire preservation seen in a single representative specimen holds broadly. The authors emphasize that their contribution is a reproducible manufacturing platform and a proof of biological feasibility, the foundations on which clinical translation can now be built. For a community of patients who have watched decades of research yield few new options, the demonstration that their tumors are infiltrated by T cells that can be grown, armed, and sent back to fight is a milestone worth noting, and one that turns a long-standing immunological question into a concrete path toward the clinic.

Subject of Research: Tumor-infiltrating lymphocyte immunotherapy for NF1/SWN-related nerve sheath tumors

Article Title: Development of TIL therapy for NF1/SWN-related nerve sheath tumors

Article References: Hao, J., Cheng, L., Zhang, C., Wang, J., Wang, H., Wu, H., & Tang, N. (2026). Development of TIL therapy for NF1/SWN-related nerve sheath tumors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04595-6

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04595-6

Keywords: TIL therapy, NF1, schwannomatosis, MPNST, adoptive cell therapy, immunotherapy, patient-derived xenograft, CD8 T cells, interleukin-2, TCR repertoire, nerve sheath tumors, preclinical study

The drug at the center of the study, AZD1390, is an orally available, brain-penetrant inhibitor of ATM kinase, a protein best known to biologists for its role in sensing and repairing damaged DNA. The Duke team, however, was interested in a different job for the molecule: blocking ferroptosis, an iron-dependent form of regulated cell death driven by the oxidative destruction of the fatty membranes that surround cells. Ferroptosis has attracted intense interest in stroke research because the brain is exceptionally rich in lipids and vulnerable to lipid peroxidation, the chain reaction in which reactive oxygen species strip electrons from cell membranes until they rupture. When blood flow to part of the brain is interrupted, the resulting shortage of oxygen and glucose sets off several forms of cellular injury, and ferroptosis is thought to be one of the important contributors to the growing zone of dead and dying tissue known as the infarct.

The researchers began their investigation far from the living brain, in cell culture and in organotypic brain slices — thin sections of brain tissue kept alive in the laboratory. When the slices were deprived of oxygen and glucose, a standard experimental model of ischemic injury, treatment with ATM inhibitors protected neurons from cell death. AZD1390, the most clinically advanced of the compounds tested, reduced measurements associated with lipid peroxidation and dampened the induction of ferroptosis-associated transcripts, the molecular signatures that cells display when this particular death program is activated. In cultured MDA-MB-231 cells exposed to erastin, a chemical that reliably triggers ferroptosis, AZD1390 reduced lipid peroxidation in a dose-dependent manner, an effect quantified with C11-BODIPY staining and confirmed across six independent biological replicates with rigorous statistical testing.

With those cellular results in hand, the team moved to mouse models of ischemic stroke using permanent middle cerebral artery occlusion, a surgical technique that blocks one of the major arteries supplying the brain and closely mimics the vascular catastrophe of a human ischemic stroke. The outcome was striking — but only in some of the animals. When AZD1390 was given orally two hours after the vessel was occluded, infarct volume measured 72 hours later was reduced by 55.6 percent in B6/J mice and by 37.1 percent in B6/NJ mice compared with vehicle-treated controls. Yet in BALB mice, a strain with a different vascular makeup, the same drug at the same dose produced no significant reduction in infarct volume at all.

The explanation, the researchers found, lay in the anatomy of the brain’s collateral circulation. B6/J and B6/NJ mice possess relatively dense connections between their major cerebral arterial territories, meaning that when the middle cerebral artery is blocked, smaller vessels can still deliver blood to the threatened tissue from neighboring vascular territories. BALB mice have far fewer of these backup connections, leaving larger swaths of brain effectively cut off from any alternative blood supply. The pattern was reinforced in a second genetic experiment: mice lacking Rabep2, a gene associated with reduced collateral vessel density, showed no infarct reduction from oral AZD1390, while wild-type and heterozygous littermates with more intact collateral networks did benefit from the treatment.

To test whether restricted vascular access was truly the limiting factor, the researchers changed the delivery strategy. Instead of giving the drug orally and relying on the bloodstream to carry it into the damaged region, they applied AZD1390 directly to the exposed cortical surface just 15 minutes after stroke induction. Under those conditions, the drug’s protective effect reappeared even in the low-collateral animals: infarct volume fell by 28.8 percent in BALB mice and by 35.2 percent in Rabep2 knockout mice. The drug, in other words, was not intrinsically powerless in these animals — it simply could not reach the tissue it was meant to protect when the vascular routes into that tissue were sparse.

The implications reach well beyond a single experimental compound. Variation in collateral blood vessels is a well-recognized feature of human neuroanatomy, and patients differ substantially in how well their brains are equipped to withstand a major arterial blockage. If vascular access to threatened brain tissue is a key determinant of therapeutic response, as the Duke findings suggest, then collateral status could become an important stratification variable in preclinical research and, eventually, in clinical trials of therapies intended to reach ischemic tissue. Treatments that look disappointing when tested across an unselected population might prove highly effective in patients with robust collateral circulation, while patients with sparse collaterals might need alternative delivery strategies or combination approaches altogether.

The authors are careful, however, to delineate the limits of what their experiments establish. The study does not prove that collateral circulation alone explains the treatment response, because the topical and oral treatment experiments differed not only in delivery route but also in timing — the topical application came earlier, at 15 minutes rather than two hours, so the earlier intervention may itself have contributed to the apparent benefit. The molecular findings likewise require further testing: although the results are consistent with reduced ferroptosis-associated lipid oxidative injury, the measurements used are not specific enough to prove that ATM-dependent ferroptosis is the sole mechanism at work. The researchers note that direct ATM target-engagement studies, genetic experiments, ferroptosis-specific rescue studies, and analyses of oxidized phospholipids will all be needed to nail down the mechanism. The study also assessed infarct volume only at the 72-hour mark and did not measure neurological function, behavioral recovery, long-term outcomes, or safety.

AZD1390 itself is an investigational agent that has previously been studied for its ability to reach the brain in other clinical contexts, which made it an attractive candidate for a stroke application. But the present findings were obtained entirely in cells, brain slices, and mice, and they do not demonstrate safety or effectiveness for people with stroke. What the study does offer is a conceptual advance: a concrete, experimentally supported reason why the same stroke therapy can produce dramatically different results across biological settings. As researchers continue the long effort to translate laboratory neuroprotection into bedside benefit, the Duke team’s work adds collateral vascular anatomy to the list of factors that must be considered — a reminder that in the brain, the road a drug must travel to reach endangered neurons may matter as much as the drug’s molecular target. The work also underscores the value of genetically diverse animal models, since a treatment evaluated only in a single high-collateral strain might have appeared uniformly effective and masked the vascular dependency entirely.

Subject of Research: The role of collateral circulation in the protective effect of ATM inhibition against ferroptosis in experimental ischemic stroke

Article Title: Study links experimental stroke protection to the brain’s backup blood vessels

Article References: Study links experimental stroke protection to the brain’s backup blood vessels. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ischemic stroke, collateral circulation, AZD1390, ATM kinase, ferroptosis, lipid peroxidation, infarct volume, middle cerebral artery occlusion, Rabep2, neuroprotection, preclinical study, brain vasculature

Vδ1 T cells belong to the gamma-delta T cell family, a small subset of lymphocytes that carry an unconventional T cell receptor built from delta and gamma chains rather than the familiar alpha and beta chains found on most T cells. What makes them attractive for cancer immunotherapy is their recognition strategy. Unlike conventional T cells, which scan cells for peptide fragments presented on major histocompatibility complex molecules, Vδ1 T cells detect stress-associated ligands and other danger signals that appear on the surface of transformed and infected cells. This MHC-independent recognition means that donor-derived Vδ1 T cells can, in principle, be infused into unrelated recipients without the severe rejection risks and graft-versus-host complications that complicate other allogeneic cell therapies. Their natural tendency to home into tissues adds a further advantage for attacking solid tumors, which are notoriously difficult for circulating immune cells to infiltrate.

Yet the same rarity that makes Vδ1 T cells immunologically convenient also makes them logistically challenging. They typically account for only a small fraction of the lymphocytes circulating in peripheral blood, so isolating enough of them for manufacturing has been a persistent obstacle. The research team, led by Shuntian Chen, Lujie Zhao, Xinrui Xie, Haoyuan Wu and senior author Hongling Wu, with institutions including the Guangzhou Institute of Respiratory Health at Guangzhou Medical University and the Guangzhou Institutes of Biomedicine and Health of the Chinese Academy of Sciences, set out to determine whether IL-18, a cytokine already known to shape the behavior of conventional T cells and natural killer cells, could unlock the proliferative potential of Vδ1 T cells as well.

The experimental design was straightforward but systematic. The researchers isolated primary human Vδ1 T cells from donor blood using magnetic bead separation and cultured them with antibodies against CD3, a coreceptor that provides T cells with an activation signal, together with interleukin-15, a growth factor widely used to drive the expansion of innate-like lymphocytes. Some cultures received IL-18 in addition; others did not. The team then tracked how fast the cells divided, what surface molecules they displayed, and how long they survived, using flow cytometry to quantify each of these parameters across the culture period.

The results on proliferation were striking. IL-18 significantly accelerated cell-cycle progression, pushing the Vδ1 T cells into division more rapidly and sustaining robust clonal expansion over the course of the culture. Crucially, this growth did not come at the cost of purity: the expanded populations retained a high proportion of genuine Vδ1 T cells, an important consideration for any manufacturing process in which overgrowth of contaminating cell types can render a product unusable. For a cell type whose scarcity has been the primary barrier to clinical translation, the ability to generate large, clean batches from a modest starting population represents a substantial advance in manufacturability.

Expansion alone, however, is not enough. Cells grown in the laboratory must remain functional when they encounter the hostile environment of a tumor, where nutrient deprivation, hypoxia and immunosuppressive signals conspire to exhaust or kill infiltrating lymphocytes. Here too, IL-18 left a measurable imprint. The cytokine-treated Vδ1 T cells showed enhanced survival during prolonged exposure to tumor cells, suggesting that IL-18 conditioning confers a degree of resistance to the apoptotic pressures of the tumor microenvironment. They also produced greater quantities of inflammatory cytokines, including interferon-gamma and tumor necrosis factor alpha, which can recruit and activate other arms of the immune response, and they migrated more effectively toward tumor-derived signals in directed migration assays.

One result complicates the otherwise rosy picture and reveals something important about how IL-18 reshapes these cells. In short-term laboratory killing assays, the IL-18-expanded Vδ1 T cells actually showed reduced contact-dependent cytotoxicity, meaning they were somewhat less efficient at directly killing tumor cells through cell-to-cell contact. This apparent deficit, however, did not translate into weaker antitumor activity in living animals. The researchers turned to RNA sequencing and quantitative PCR to probe the transcriptional shifts underlying these changes, finding alterations in gene programs associated with cell survival, inflammatory signaling and apoptosis regulation, including changes in genes such as BAX, a pro-apoptotic regulator, and death receptor pathway components. The molecular profile suggested that IL-18 redirects the cells away from a purely cytotoxic specialization and toward a more durable, inflammation-oriented and tissue-infiltrating state.

The decisive test came in an animal model. The team used mice bearing xenografts of A549 cells, a human lung carcinoma line derived from a non-small cell lung cancer, and compared the therapeutic effects of IL-18-conditioned Vδ1 T cells against control Vδ1 T cells expanded without the cytokine. Bioluminescence imaging was used to track tumor burden over time. The IL-18-expanded cells suppressed tumor growth more effectively and, most importantly, significantly prolonged the survival of the tumor-bearing mice. The in vivo superiority of the IL-18-conditioned product, despite its reduced immediate killing capacity in vitro, underscores a recurring lesson in cell therapy development: laboratory killing assays do not always predict therapeutic performance, and properties such as persistence, migration and cytokine output can matter more for solid tumor control than raw cytotoxicity measured over a few hours in a culture dish.

The translational implications are considerable. Because Vδ1 T cells can be used in an allogeneic, off-the-shelf format, an optimized expansion protocol could enable the production of standardized cell products from healthy donors, manufactured in advance and administered to many patients without the individualized engineering timelines required for autologous therapies such as CAR-T cells. The study also did not involve clinical research on human subjects; all animal work was approved by the Institutional Animal Care and Use Committee of the Guangzhou Institutes of Biomedicine and Health, and the findings remain at the preclinical stage. Moving from xenograft models to human trials will require demonstrating safety, dosing feasibility and efficacy in patients, and the authors note that the work was supported by the National Natural Science Foundation of China and the National Key Research and Development Program of China.

For the broader field of gamma-delta T cell immunotherapy, the study adds IL-18 to the toolkit of cytokines that can be deployed to tune cell products for specific therapeutic goals. Interleukin-15 has long served as the workhorse expansion factor for innate-like lymphocytes, but IL-18 appears to impart a complementary identity, one that favors longevity, inflammatory potency and tumor homing over immediate cytolytic function. As researchers continue to engineer gamma-delta T cells with chimeric antigen receptors and other enhancements, the ability to shape their baseline fitness through cytokine conditioning could prove essential. If the results hold up in clinical testing, a simple change to the culture recipe, the addition of a single signaling molecule, may help transform a scarce circulating curiosity into a scalable weapon against some of the hardest tumors to treat.

Subject of Research: IL-18-driven expansion and functional enhancement of human Vδ1 gamma-delta T cells for solid tumor immunotherapy

Article Title: IL‑18 improves the expansion and functional fitness of human Vδ1 T cells for superior solid tumor immunotherapy

Article References: Chen, S., Zhao, L., Xie, X., Wu, H., Hu, S., Han, X., Li, T., Chen, J., & Wu, H. (2026). IL‑18 improves the expansion and functional fitness of human Vδ1 T cells for superior solid tumor immunotherapy. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09079-w

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09079-w

Keywords: Vδ1 T cells, gamma-delta T cells, IL-18, interleukin-15, immunotherapy, solid tumors, lung cancer, adoptive cell therapy, cytokines, tumor microenvironment, allogeneic cell therapy, preclinical study

The rationale for the dual approach rests on decades of immunological evidence. TL1A, the only known ligand for the death receptor 3 signaling receptor, is strongly upregulated in the inflamed intestinal tissue of patients with inflammatory bowel disease. When it engages DR3, it activates NF-κB and MAPK pathways inside T cells, promoting co-stimulation, inflammatory cytokine secretion, and even the intestinal fibrosis that complicates long-standing disease. Meanwhile, IL-12 and IL-23 are heterodimeric cytokines that share the p40 subunit and steer T cell differentiation down two destructive paths: IL-12 drives Th1 cells and interferon-gamma production through STAT4, while IL-23 stabilizes Th17 cells and their signature IL-17 output through STAT3. Crucially, these pathways do not operate in isolation. TL1A enhances IL-12-mediated Th1 polarization and IL-23-driven Th17 differentiation, forming a feedforward loop that amplifies mucosal damage. Existing single-target biologics, including ustekinumab and risankizumab, leave 30 to 50 percent of patients without durable remission, precisely because redundant and interconnected pathways allow inflammation to escape.

To solve the engineering challenge of hitting two targets with one molecule, the team used a common light chain architecture combined with knobs-into-holes Fc engineering, which forces the two different heavy chains to pair correctly while eliminating light chain mispairing, a notorious problem in bispecific antibody manufacturing. The resulting antibody, named KA-4316, was produced in ExpiCHO cells at high expression levels of 478.29 milligrams per liter and purified to exceptional monomer purity of 97.35 percent. Size-exclusion chromatography, SDS-polyacrylamide gel electrophoresis, and differential scanning fluorimetry confirmed robust assembly at the expected 144 kilodalton molecular weight and a favorable melting temperature of 68.62 degrees Celsius. These biophysical benchmarks matter enormously for translational development, because a bispecific antibody that aggregates or assembles inconsistently cannot be manufactured reliably at clinical scale.

Functional characterization showed that KA-4316 binds its two targets with sub-nanomolar affinity: 8.72 × 10⁻¹¹ molar for human TL1A and 2.50 × 10⁻¹⁰ molar for IL-12/23p40. Reciprocal sequential biolayer interferometry and sandwich ELISA assays confirmed that the antibody can engage both antigens at the same time without steric interference between its two arms. The antibody recognized both soluble and membrane-associated TL1A, and it bound the cynomolgus monkey orthologs of both targets, a critical property for non-human primate pharmacology, while showing no detectable binding to the mouse versions. In neutralization assays, KA-4316 blocked the interaction of IL-12 and IL-23 with the IL-12Rβ1 receptor subunit with IC50 values of 12.88 and 16.81 nanomolar respectively, and it prevented TL1A from engaging DR3 with an IC50 of 2.76 nanomolar, with weaker activity against the decoy receptor DcR3.

In cell-based assays, the bispecific antibody functioned as a potent dual inhibitor of inflammatory signaling. It suppressed TL1A-driven NF-κB activation in DR3 reporter cells with an IC50 of 0.49 nanomolar, neutralized TL1A-induced apoptosis in TF-1 cells, blocked IL-12-induced STAT4 activation and interferon-gamma secretion from NK cells, and dampened IL-23-mediated STAT3 activation. Most tellingly, when human peripheral blood mononuclear cells were stimulated with the synergistic combination of TL1A, IL-12, and IL-18, KA-4316 suppressed interferon-gamma release with an IC50 of 0.47 nanomolar, outperforming either parental monospecific antibody alone and matching their combined administration. Chou-Talalay combination index analysis of the parental antibody mixture produced values below one across multiple effect levels, quantitatively confirming pharmacological synergy between the two pathways. The authors note candidly that the bispecific format itself offered only a modest, statistically insignificant potency improvement over simply mixing the two parental antibodies, meaning the value of the molecule lies in its convenience, pharmacokinetics, and unified manufacturing rather than intrinsic functional superiority.

To make the antibody clinically practical, the team engineered a half-life-extended variant called KA-5817 by introducing the YTE mutations, M252Y, S254T, and T256E, into the Fc region. These mutations enhance binding to the neonatal Fc receptor at acidic pH, which recycles IgG molecules and prolongs their persistence in circulation. In FcRn-humanized mice receiving a single 10 milligram per kilogram intravenous dose, KA-5817 exhibited a serum half-life of 21.53 days, compared with 8.32 days for the original KA-4316, a nearly threefold extension that could translate into less frequent dosing and better patient compliance. A pilot pharmacokinetic and safety study in cynomolgus monkeys at 3 and 10 milligrams per kilogram showed dose-dependent elimination kinetics complicated by anti-drug antibody formation at the higher dose, but comprehensive hematology and serum biochemistry revealed no treatment-related hematologic, hepatic, or renal toxicity at either dose level.

The decisive test came in a clinically translatable colitis model using C57BL/6 mice triple-humanized for TL1A, IL23A, and IL12B, meaning the animals carry human versions of all three relevant genes. Acute colitis was induced with dextran sulfate sodium in drinking water for six days, and mice received intravenous antibody treatments on days 0, 3, and 7 at a total dose of 20 milligrams per kilogram. Compared with an isotype control, single monospecific antibodies against TL1A or IL-12/23p40 produced only partial relief. KA-5817, however, dramatically reduced weight loss, disease activity scores combining stool consistency and rectal bleeding, and colon shortening, performing on par with an equimolar physical mixture of the two monospecific antibodies. Histological examination of colon tissue confirmed the benefit: where isotype-treated mice showed extensive epithelial erosion, crypt loss, and dense inflammatory infiltration, KA-5817-treated animals retained intact crypt architecture with substantially reduced immune cell invasion of the mucosa.

Mechanistic analysis of immune cells isolated from the colonic lamina propria revealed how the antibody works. Flow cytometry showed that KA-5817 significantly reduced the frequency of pathogenic Th1 cells, the CD4-positive interferon-gamma producers, while Th17 cells showed a trend toward reduction, and regulatory T cell proportions were unchanged. In colon tissue homogenates, the antibody substantially lowered concentrations of the pro-inflammatory cytokines TNF-α and IL-6 and diminished phosphorylated STAT3, the downstream signaling node through which IL-23 sustains Th17-driven autoimmunity. Together these data sketch a coherent mechanism: dual blockade breaks the synergistic feedforward loop between TL1A and the IL-12/23 axis, restrains the differentiation and activity of the two T cell subsets that dominate intestinal pathology, and calms cytokine production in the inflamed tissue itself.

The findings arrive at a moment of intense commercial and clinical interest in TL1A as a drug target. Pfizer’s anti-TL1A monoclonal antibody PF-06480605 has already shown promise in patients, and PF-07261271, a TL1A × IL-12/23p40 bispecific developed by Pfizer and Roche, is in phase 2b trials for ulcerative colitis using CrossMab technology, which the authors argue suffers from structural asymmetry and intellectual property constraints. Their common light chain design, they contend, simplifies manufacturing and analytical characterization while maintaining potency. The team is also forthright about limitations: the DSS colitis model is driven largely by acute epithelial injury and innate immunity rather than the chronic, T cell-mediated immunopathology of human disease, and the monkey pharmacokinetic study used only one animal per dose. Future work in adoptive T cell transfer models, which generate persistent Th1 and Th17-dominated inflammation, will be needed to confirm translational potential. Still, with strong preclinical efficacy, favorable safety signals, and a manufacturable molecular design, this dual-targeting strategy represents a compelling next-generation candidate for patients whose inflammation currently slips past single-pathway drugs.

Subject of Research: Development of a TL1A and IL-12/23p40 bispecific antibody for treating inflammatory bowel disease

Article Title: Bispecific antibodies targeting TL1A and IL-12/23p40 suppress pathogenic Th1/Th17 responses and ameliorate colitis in mice

Article References: Li, X., Peng, H., Hao, F., Gu, Y., Ning, J., & Yu, C. (2026). Bispecific antibodies targeting TL1A and IL-12/23p40 suppress pathogenic Th1/Th17 responses and ameliorate colitis in mice. iScience, 29(11), Article 117795. https://doi.org/10.1016/j.isci.2026.117795

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117795

Keywords: bispecific antibody, TL1A, IL-12/23p40, inflammatory bowel disease, colitis, Th1 cells, Th17 cells, DR3, STAT3, FcRn, half-life extension, preclinical study

The scale of the problem is considerable. According to the authors, roughly 2 percent of all pregnancies in the United States, and between 1 and 2 percent worldwide, are ectopic. In the United States alone, that translates to approximately 100,000 ectopic pregnancies each year, and over the past six years about 30 women have died annually from the condition. About 98 percent of ectopic implantations happen in the fallopian tubes, placing women at direct risk of tubal rupture, internal bleeding and death. The clinical stakes are compounded by the limitations of the tools currently available to detect and end these pregnancies, which are far from perfect even in well-resourced health systems.

The standard diagnostic tool, transvaginal ultrasound, carries a misdiagnosis rate of about 10 percent, meaning a meaningful fraction of ectopic pregnancies are either missed or incorrectly identified. The primary drug used to end an ectopic pregnancy, methotrexate, has an even higher failure rate. Methotrexate works by causing embryonic cells to stop dividing, but even when it is effective it comes with a range of potential side effects, including nausea, vomiting, diarrhea, elevated liver enzymes, kidney damage and lung disease. When medication fails or diagnosis comes too late, surgery becomes necessary, and surgery on the fallopian tube carries its own consequences for future fertility.

Olena Taratula of the OSU College of Pharmacy, who led the study, framed the shortcomings of the current standard of care bluntly. Current strategies, she said, which involve attempted diagnosis via ultrasound, treatment with methotrexate, and surgery if necessary, are associated with the risk of tubal rupture and reduced fertility. She also noted an increased risk of recurrence: a woman who has had one ectopic pregnancy is 10 percent more likely to have a second one. Together, these factors create a clinical landscape in which earlier, more accurate diagnosis and less destructive treatment options could meaningfully improve outcomes for tens of thousands of women each year.

The alternative explored by Taratula, postdoctoral scholar Karthickraja Duraisamy and collaborators at Oregon State and Oregon Health & Science University is a nanomedicine approach built on specially engineered magnetic nanoparticles. Nanoparticles are tiny pieces of matter, as small as one-billionth of a meter, small enough to travel through the bloodstream and accumulate in specific tissues. The particles developed for this study are cobalt-doped soft ferromagnetic iron oxide nanoparticles, administered intravenously. In pregnant mice, the particles accumulated in the placenta, the organ that nourishes and maintains the fetus through the umbilical cord, and that selective accumulation is the key to both halves of the platform.

The diagnostic function exploits that accumulation directly. Once the nanoparticles are concentrated in placental tissue, the organ can be clearly seen through magnetic resonance imaging. Effective detection of the growing placenta, Taratula explained, greatly improves the accuracy and timeliness of ectopic pregnancy identification. In a human patient, an MRI scan after particle administration would quickly reveal whether the placenta is where it is supposed to be. If it is, the patient would know she does not have an ectopic pregnancy, and the embryo would be unaffected by the particles, which do not cross the placental barrier. If the placenta is instead located in a fallopian tube or another incorrect site, the same scan provides a precise target for treatment.

That treatment is where the magnetic properties of the particles come into play. When exposed to an alternating magnetic field, the cobalt-doped iron oxide nanoparticles heat up. This magnetic hyperthermia is deliberately controlled: the team developed an MRI-guided magnetic nanoplatform for localized hyperthermia of pregnancy-associated tissue at temperatures of less than or equal to 45 degrees Celsius. At that temperature, applied non-invasively from outside the body, the heat irreparably disrupts placental function, ending the pregnancy without drugs and without incisions. Because the heat is generated only where the particles have accumulated, the thermal effect is confined to the misplaced gestational tissue rather than the surrounding anatomy.

The results in the animal model were striking. In pregnant mice, the platform selectively disrupted gestational sacs while preserving surrounding uterine tissue and fertility, according to Duraisamy, who said the findings support its potential as a minimally invasive treatment for ectopic pregnancy. Preserving fertility is a central goal, given that surgical removal of part or all of a fallopian tube is a known driver of both reduced fertility and the elevated risk of future ectopic pregnancies. A therapy that ends a non-viable pregnancy while leaving the reproductive tract intact would represent a fundamental shift in how the condition is managed.

Taratula emphasized that the study was designed to answer two specific questions: whether the nanoparticle could identify and visualize the developing placenta, and whether it could deliver effective magnetic hyperthermia. Both were demonstrated, and she described the results as highly promising while stressing the road ahead. In the coming years, she said, the team needs to validate the findings in other animal models to further advance the application of this technology. Translation from mice to humans will require establishing safe dosing, particle clearance, imaging protocols and treatment parameters in larger animal studies before any clinical trial could begin, a process that typically spans years.

The research was contributed to by Oleh Taratula, Prem Singh, Akshay Vyawahare, Ana Paula Mesquita Souza and Kongbrailatpam Shitaljit Sharma of Oregon State, and was supported by the College of Pharmacy, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the OHSU School of Medicine. If the platform continues to perform in further preclinical work, it could eventually offer clinicians a single intravenous agent that answers the two most urgent questions in suspected ectopic pregnancy, where is the placenta and how can the pregnancy be ended safely, with an MRI scan and a magnetic field rather than a scalpel. For the roughly 100,000 American women each year who face this diagnosis, that combination of certainty and gentleness would mark a profound improvement over the options available today.

Subject of Research: Nanoparticle-mediated MRI diagnosis and magnetic hyperthermia treatment of ectopic pregnancy

Article Title: Researchers push toward improved care for women with dangerous pregnancy condition

Article References: Researchers push toward improved care for women with dangerous pregnancy condition. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ectopic pregnancy, nanoparticles, magnetic hyperthermia, MRI, iron oxide, placenta, methotrexate, fertility, Oregon State University, Biomaterials, preclinical study, women's health